Table 1.
Patient clinical and biological characteristics and comparison between patients with detectable versus undetectable HPV ctDNA.
| Characteristics | All patients | Detectable HPV ctDNA at baseline | Undetectable HPV ctDNA at baseline | |
|---|---|---|---|---|
| Total | n = 94 | n = 59 | n = 35 | P |
| Age (in years) | ||||
| Median | 50 (24–80) | 50 (24–80) | 51 (24–78) | |
| FIGO stage (2018) | ||||
| I | 9 (9%) | 4 (7%) | 5 (14%) | 0.02(I/II vs III/IV) |
| II | 17 (18%) | 7 (12%) | 10 (29%) | |
| III | 58 (62%) | 39 (66%) | 19 (54%) | |
| IV | 10 (11%) | 9 (15%) | 1 (3%) | |
| Lymph node | ||||
| (N0) | 32 (34%) | 16 (27%) | 16 (46%) | 0.08 |
| (N+) | 62 (66%) | 43 (73%) | 19 (54%) | |
| Para-aortic lymph node | ||||
| (N0) | 72 (77%) | 40 (68%) | 32 (91%) | 0.01 |
| (N+) | 22 (23%) | 19 (32%) | 3 (9%) | |
| Pelvic lymph node | ||||
| (N0) | 34 (36%) | 18 (31%) | 16 (46%) | 0.18 |
| (N+) | 60 (64%) | 41 (69%) | 19 (54%) | |
| Histology | ||||
| SCC | 82 (87%) | 52 (88%) | 30 (86%) | 0.76(SCC vs ADK+ASC) |
| Adenocarcinoma | 10 (11%) | 6 (10%) | 4 (11%) | |
| ASC | 2 (2%) | 1 (2%) | 1 (3%) | |
| HPV type | ||||
| HPV16 | 76 (81%) | 47 (80%) | 29 (83%) | 0.79 |
| HPV18 | 18 (19%) | 12 (20%) | 6 (17%) | |
| HPV copy number | ||||
| <5 copies/cell | 32 (34%) | 13 (22%) | 19 (64%) | 0.003 |
| ≥5 copies/cell | 62 (66%) | 46 (78%) | 16 (46%) | |
| Initial treatment | Not tested | |||
| Surgery | 19 (20%) | 9 (15%) | 10 (28%) | |
| Chemoradiotherapy | 61 (65%) | 39 (66%) | 22 (63%) | |
| Neo-chemotherapy | 14 (15%) | 11 (19%) | 3 (9%) | |
Abbreviations: ADK, adenocarcinoma; ASC, adenosquamous carcinoma; P, Fisher test; SCC, squamous cell carcinoma.